MovDisordV3, PascalFrancis, Checkpoint, bibRecord, 001429

The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease : A double blind placebo-controlled pilot study

Identifieur interne : 001429 ( PascalFrancis/Checkpoint ); précédent : 001428; suivant : 001430

The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease : A double blind placebo-controlled pilot study

Auteurs : Tanya Gurevich [Israël] ; Chava Peretz [Israël] ; Orna Moore [Israël] ; Nina Weizmann [Israël] ; Nir Giladi [Israël]

Source :

Movement disorders [ 0885-3185 ] ; 2007.

RBID : Pascal:07-0263071

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Parkinson maladie, Bontoxilysin, Muscle strié, Congélation, Etude double insu, Placebo.
Wicri :
- topic : Congélation.

English descriptors

KwdEn :
- Bontoxilysin, Double blind study, Freezing, Nervous system diseases, Parkinson disease, Placebo, Striated muscle.

Abstract

Objective: To assess the effect on freezing of gait (FOG) of botulinum toxin type A (BTX-A) injections in advanced Parkinson's disease (PD) patients. Method: BTX-A 150 IU or normal saline was injected into each leg's calf muscles by a blinded investigator. FOG severity was assessed at set intervals (6-month follow-up). Results: Eleven age- and disease severity-matched PD patients with disabling FOG participated. Six patients received BTX-A and 5 received saline. No improvement was observed in either group over time. Leg weakness and falls lead to early termination. Conclusion: BTX-A injections to the legs did not improve FOG and might increase fall risk.

Affiliations:

Israël

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001686
to stream PascalFrancis, to step Curation: 001635

Links to Exploration step

Pascal:07-0263071

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease : A double blind placebo-controlled pilot study</title>
<author><name sortKey="Gurevich, Tanya" sort="Gurevich, Tanya" uniqKey="Gurevich T" first="Tanya" last="Gurevich">Tanya Gurevich</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel-Aviv Sourasky Medical Center</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Tel-Aviv</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Sackler Faculty of Medicine, Tel-Aviv University</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Tel-Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Peretz, Chava" sort="Peretz, Chava" uniqKey="Peretz C" first="Chava" last="Peretz">Chava Peretz</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel-Aviv Sourasky Medical Center</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Tel-Aviv</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Sackler Faculty of Medicine, Tel-Aviv University</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Tel-Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moore, Orna" sort="Moore, Orna" uniqKey="Moore O" first="Orna" last="Moore">Orna Moore</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel-Aviv Sourasky Medical Center</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Tel-Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Weizmann, Nina" sort="Weizmann, Nina" uniqKey="Weizmann N" first="Nina" last="Weizmann">Nina Weizmann</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel-Aviv Sourasky Medical Center</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Tel-Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel-Aviv Sourasky Medical Center</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Tel-Aviv</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Sackler Faculty of Medicine, Tel-Aviv University</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Tel-Aviv</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0263071</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0263071 INIST</idno>
<idno type="RBID">Pascal:07-0263071</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001686</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001635</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001429</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease : A double blind placebo-controlled pilot study</title>
<author><name sortKey="Gurevich, Tanya" sort="Gurevich, Tanya" uniqKey="Gurevich T" first="Tanya" last="Gurevich">Tanya Gurevich</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel-Aviv Sourasky Medical Center</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Tel-Aviv</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Sackler Faculty of Medicine, Tel-Aviv University</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Tel-Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Peretz, Chava" sort="Peretz, Chava" uniqKey="Peretz C" first="Chava" last="Peretz">Chava Peretz</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel-Aviv Sourasky Medical Center</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Tel-Aviv</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Sackler Faculty of Medicine, Tel-Aviv University</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Tel-Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moore, Orna" sort="Moore, Orna" uniqKey="Moore O" first="Orna" last="Moore">Orna Moore</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel-Aviv Sourasky Medical Center</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Tel-Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Weizmann, Nina" sort="Weizmann, Nina" uniqKey="Weizmann N" first="Nina" last="Weizmann">Nina Weizmann</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel-Aviv Sourasky Medical Center</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Tel-Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel-Aviv Sourasky Medical Center</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Tel-Aviv</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Sackler Faculty of Medicine, Tel-Aviv University</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Tel-Aviv</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bontoxilysin</term>
<term>Double blind study</term>
<term>Freezing</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Placebo</term>
<term>Striated muscle</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Bontoxilysin</term>
<term>Muscle strié</term>
<term>Congélation</term>
<term>Etude double insu</term>
<term>Placebo</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Congélation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective: To assess the effect on freezing of gait (FOG) of botulinum toxin type A (BTX-A) injections in advanced Parkinson's disease (PD) patients. Method:  BTX-A 150 IU or normal saline was injected into each leg's calf muscles by a blinded investigator. FOG severity was assessed at set intervals (6-month follow-up). Results: Eleven age- and disease severity-matched PD patients with disabling FOG participated. Six patients received BTX-A and 5 received saline. No improvement was observed in either group over time. Leg weakness and falls lead to early termination. Conclusion: BTX-A injections to the legs did not improve FOG and might increase fall risk.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>22</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease : A double blind placebo-controlled pilot study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GUREVICH (Tanya)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>PERETZ (Chava)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MOORE (Orna)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>WEIZMANN (Nina)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GILADI (Nir)</s1>
</fA11>
<fA14 i1="01"><s1>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel-Aviv Sourasky Medical Center</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Sackler Faculty of Medicine, Tel-Aviv University</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>880-883</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000149445250220</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>12 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0263071</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Objective: To assess the effect on freezing of gait (FOG) of botulinum toxin type A (BTX-A) injections in advanced Parkinson's disease (PD) patients. Method:  BTX-A 150 IU or normal saline was injected into each leg's calf muscles by a blinded investigator. FOG severity was assessed at set intervals (6-month follow-up). Results: Eleven age- and disease severity-matched PD patients with disabling FOG participated. Six patients received BTX-A and 5 received saline. No improvement was observed in either group over time. Leg weakness and falls lead to early termination. Conclusion: BTX-A injections to the legs did not improve FOG and might increase fall risk.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Muscle strié</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Striated muscle</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Músculo estriado</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Congélation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Freezing</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Congelación</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Etude double insu</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Double blind study</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Estudio doble ciego</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Placebo</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Placebo</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Placebo</s0>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>176</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Israël</li>
</country>
</list>
<tree><country name="Israël"><noRegion><name sortKey="Gurevich, Tanya" sort="Gurevich, Tanya" uniqKey="Gurevich T" first="Tanya" last="Gurevich">Tanya Gurevich</name>
</noRegion>
<name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name>
<name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name>
<name sortKey="Gurevich, Tanya" sort="Gurevich, Tanya" uniqKey="Gurevich T" first="Tanya" last="Gurevich">Tanya Gurevich</name>
<name sortKey="Moore, Orna" sort="Moore, Orna" uniqKey="Moore O" first="Orna" last="Moore">Orna Moore</name>
<name sortKey="Peretz, Chava" sort="Peretz, Chava" uniqKey="Peretz C" first="Chava" last="Peretz">Chava Peretz</name>
<name sortKey="Peretz, Chava" sort="Peretz, Chava" uniqKey="Peretz C" first="Chava" last="Peretz">Chava Peretz</name>
<name sortKey="Weizmann, Nina" sort="Weizmann, Nina" uniqKey="Weizmann N" first="Nina" last="Weizmann">Nina Weizmann</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001429 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 001429 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:07-0263071
   |texte=   The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease : A double blind placebo-controlled pilot study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease : A double blind placebo-controlled pilot study

The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease : A double blind placebo-controlled pilot study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri